Drug profile · INN
copanlisib
ALIQOPA
copanlisib (ALIQOPA) is a pi3-kinase p110-delta subunit inhibitor.
EMA: application withdrawn
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — copanlisib
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
copanlisib (ALIQOPA) is a pi3-kinase p110-delta subunit inhibitor.
Key facts
INN copanlisib
Brand ALIQOPA
Mechanism PI3-kinase p110-delta subunit inhibitor
Target Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Mechanism of action
PI3-kinase p110-delta subunit inhibitor
Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is copanlisib?
copanlisib (ALIQOPA) is a pi3-kinase p110-delta subunit inhibitor.
What is the brand name for copanlisib?
ALIQOPA is a marketed brand name for copanlisib. Check FDA Drugs@FDA for the current US label holder and prescribing information.